Gadoxetic Acid Disodium (Primovist, BAY86-4873)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diagnostic Imaging
Conditions
Diagnostic Imaging
Trial Timeline
Mar 11, 2008 → Feb 18, 2015
NCT ID
NCT01411449About Gadoxetic Acid Disodium (Primovist, BAY86-4873)
Gadoxetic Acid Disodium (Primovist, BAY86-4873) is a pre-clinical stage product being developed by Bayer for Diagnostic Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT01411449. Target conditions include Diagnostic Imaging.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00908596 | Approved | Completed |
| NCT01411449 | Pre-clinical | Completed |
| NCT00924248 | Pre-clinical | Completed |
| NCT00526188 | Phase 3 | Completed |
Competing Products
11 competing products in Diagnostic Imaging
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS) | Johnson & Johnson | Phase 3 | 77 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Iopromide (Ultravist, BAY86-4877) | Bayer | Pre-clinical | 20 |
| BAY86-4367 + BAY86-4367 | Bayer | Phase 1 | 30 |
| F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) | Bayer | Phase 1 | 30 |
| Ultravist (Iopromide, BAY86-4877) | Bayer | Pre-clinical | 20 |
| Gadopentetate dimeglumine (Magnevist, BAY86-4882) | Bayer | Pre-clinical | 20 |
| Gadobutrol (Gadavist, Gadovist, BAY86-4875) + Gadoteridol (ProHance) | Bayer | Phase 3 | 74 |
| Xenetix + Visipaque | Guerbet | Approved | 77 |
| Iobitridol | Guerbet | Approved | 77 |
| Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine) | Guerbet | Phase 3 | 69 |